DEC 29, 2016 8:02 AM PST

Positive Results for Ocrelizumab Raise Hope for MS Cure

WRITTEN BY: Xuan Pham

A drug that weakens the immune system is showing big promise as potentially the first treatment option for multiple sclerosis (MS). In three large-scale, multi-center clinical trials, the drug ocrelizumab was shown to be effective against both types of multiple sclerosis, the progressive form and the relapsing remitting form.

"It's very significant because this is the first time a phase three trial has been positive in primary progressive MS,” said Gavin Giovannoni, professor at the Barts and The London School of Medicine and Dentistry, and co-author of the study, published in the New England Journal of Medicine.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

To combat a rogue immune system, researchers focused on a drug that can quell the assault on the myelin sheath. Indeed, ocrelizumab, patented by Hoffman-La Roche, prevents the B cells from attacking the protective myelin covers. 

Tested in patients with both forms of MS, the drug seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The results shown by these studies have the potential to change how we approach treating both relapsing and primary progressive MS,” said Giovannoni.

The drug is under evaluation from both the European Medicines Agency and the U.S. FDA.

Despite the big promises for MS, researchers are cautiously optimistic as a drug that dampens the immune system could incur other health troubles, such as infection and cancer. As such, they are rigorously testing for side effects associated with the drug.

"This is the first drug to show a significant effect in slowing disability progression in a phase three trial in primary progressive multiple sclerosis and therefore represents a landmark study in the field,” said Peter Calabresi, professor of Neurology from Johns Hopkins University who was not associated with the study.

Additional sources: BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 06, 2020
Clinical & Molecular DX
Gut Feeling: Spotting the Early Signs of Gastric Cancer
AUG 06, 2020
Gut Feeling: Spotting the Early Signs of Gastric Cancer
In a study published in Science Advances, scientists propose a new method for diagnosing gastric cancer, the third leadi ...
AUG 13, 2020
Clinical & Molecular DX
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
AUG 13, 2020
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
A staggering 1 in 8 women in the U.S. will develop an aggressive form of breast cancer in their lifetime, making it the ...
AUG 27, 2020
Clinical & Molecular DX
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
AUG 27, 2020
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
  Many diseases such as breast cancer have both a strong genetic component, coupled with a variety of environmental ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
NOV 11, 2020
Clinical & Molecular DX
Smart Mask Detects COVID Infections, Sends Alert to Phone
NOV 11, 2020
Smart Mask Detects COVID Infections, Sends Alert to Phone
  This week, the Centers for Disease Control and Prevention issued new guidance to put the “mask debate&rdquo ...
Loading Comments...